HIV Infections Clinical Trial
Official title:
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)
NCT number | NCT00000819 |
Other study ID # | ACTG 271 |
Secondary ID | 11247 |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Est. completion date | September 1996 |
Verified date | October 2021 |
Source | National Institute of Allergy and Infectious Diseases (NIAID) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To determine the efficacy and safety of prednisone in patients with HIV-associated nephropathy. To determine the effects of prednisone on serum creatinine, urinary protein, and creatinine clearance. HIV-associated nephropathy is characterized by heavy proteinuria, rapidly progressive renal insufficiency, and distinct nephropathologic changes. The syndrome most often occurs in patients with advanced HIV disease. Little is known about the effects of corticosteroids on the progression of HIV disease. In light of the possible beneficial effects of corticosteroids on HIV-associated nephropathy, a controlled trial using prednisone is warranted.
Status | Completed |
Enrollment | 54 |
Est. completion date | September 1996 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria Patients must have: - HIV infection. - Biopsy-confirmed glomerulosclerosis and/or mesangial proliferation within 90 days prior to study entry. - Mild to severe renal insufficiency that is stable or worsening. - No AIDS-defining opportunistic infections or malignancies. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Poorly controlled hypertension or diabetes mellitus. - Peptic ulcer disease with gastrointestinal bleeding. - Active symptomatic bacterial, protozoal, fungal, or viral infections (other than HIV disease). - Superimposed renal disease that is due to processes other than focal glomerulosclerosis or mesangial proliferation, including but not limited to obstructive uropathy, acute tubular necrosis, and prerenal azotemia. - Emotional problems sufficient to prevent adequate compliance with study therapy. Concurrent Medication: Excluded: - IV amphotericin B. - IV aminoglycosides. - IV foscarnet. - IV pentamidine. - Trimethoprim > 200 mg/day. - Nonsteroidal anti-inflammatory agents. - Angiotensin converting enzyme inhibitors (benzapril, captopril, enalapril, fosinopril, lisinopril, guinapril, and ramipril) except for refractory hypertension. Concurrent Treatment: Excluded: - Iodinated radiocontrast dye. Patients with the following prior conditions are excluded: - Active pulmonary disease on chest radiograph within 60 days prior to study entry. - CMV retinitis on ophthalmologic evaluation within 60 days prior to study entry. - Positive blood culture for mycobacteria 10-60 days prior to study entry. Prior Medication: Excluded: - Prior corticosteroid therapy for HIVAN. - Corticosteroid therapy for any indication within 30 days prior to study entry. - Continuous nonsteroidal anti-inflammatory agents for more than 15 days during the 4 weeks prior to study entry. Prior Treatment: Excluded within 30 days prior to study entry: - Dialysis for acute or chronic renal failure. - Iodinated radiocontrast dye. Required: - Stable antiretroviral therapy with AZT alone or in combination with ddI, ddC, or d4T for at least 4 weeks unless contraindicated. - PCP prophylaxis with TMP/SMX, pentamidine aerosol, dapsone, or atovaquone. - MAC prophylaxis with rifabutin or clarithromycin for patients with CD4 count < 100 cells/mm3. - Mycobacterium tuberculosis prophylaxis with isoniazid or another accepted regimen for patients with a positive or previously positive tuberculin test and for anergic patients who are known household or close contacts of infectious TB patients or who are from groups in which the prevalence of TB is 10 percent or higher. - Investigational drugs unless exempted by protocol chair. - Other medications unless expressly prohibited. Active alcohol or drug abuse. |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins Adult AIDS CRS | Baltimore | Maryland |
United States | Case CRS | Cleveland | Ohio |
United States | MetroHealth CRS | Cleveland | Ohio |
United States | Indiana Univ. School of Medicine, Infectious Disease Research Clinic | Indianapolis | Indiana |
United States | UCLA CARE Center CRS | Los Angeles | California |
United States | Beth Israel Med. Ctr. (Mt. Sinai) | New York | New York |
United States | Ucsf Aids Crs | San Francisco | California |
United States | Harbor-UCLA Med. Ctr. CRS | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) | Upjohn |
United States,
Kalayjian R, Phinney M, Austen J, Gripshover B, Carey J, Rahman M, Weigel K, Smith MC. Prednisone improves renal function in HIV-associated nephropathy (HIVAN). Natl Conf Hum Retroviruses Relat Infect (2nd). 1995 Jan 29-Feb 2:154
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |